Daiichi Sankyo Co., Ltd.

Quick facts

Marketed products

• olmesartan medoxomil and a CCB · Cardiovascular
  This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.
• olmesartan medoxomil and a diuretic · Cardiovascular
  Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure.

Phase 3 pipeline

• Alendronate sodium hydrate · Bone metabolism / Osteoporosis
  Alendronate sodium inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• CS-3150 · Cardiovascular
  CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure.
• CS-8958 · Infectious Disease
  CS-8958 is a neuraminidase inhibitor that prevents influenza virus release from infected cells by blocking sialic acid cleavage.
• DS-5565 · Neurology / Pain Management
  DS-5565 is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.
• DS-8201a · Oncology
  DS-8201a is an anti-HER2 antibody-drug conjugate that delivers a cytotoxic payload directly to HER2-expressing cancer cells.
• DU-176b (edoxaban) · Cardiovascular
  Edoxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.

Phase 2 pipeline

• CPT-11 based regimens · Oncology
  CPT-11 is a topoisomerase I inhibitor that works by stabilizing the cleavage complex of DNA and RNA, thereby inhibiting DNA replication and transcription.
• DS-5141b
• DU-176b tablets · Psychiatry
  DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.
• Platinum analogues
• PLX3397

Phase 1 pipeline

• DS-1123
• DS-5670a
• DS-6016a
• DS-6051b
• DS-8895a
• DS1040b
• Steroid Containing Mouthwash

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Daiichi Sankyo Co., Ltd. portfolio CI brief
• Daiichi Sankyo Co., Ltd. pipeline updates RSS